2025-04-02 12:33:15
Latest Post
GAIL opens fresh round of inviting proposals for equity investment in Start-Ups
NRF expands production capacity with new factory of 11900m2 in Poland
Tata Communications a Leader for 12th consecutive year in Gartner Magic Quadrant
Bharti Airtel and Nokia expand core network collaboration to speed-up new 5G service delivery
Emerald Finance infuses ₹10 Cr with Preferential Allotment of Equity Shares to Promoters, FIIs and HNIs
Stock Report
Suven Pharmaceuticals Q4 FY2022 consolidated PAT slides QoQ to Rs. 91.66 crores
Posted On : 2022-05-09 14:19:52( TIMEZONE : IST )
Suven Pharmaceuticals Limited has reported Consolidated financial results for the period ended March 31, 2022.
Financial Results (Q4 FY2022) - QoQ Comparison
The company has reported total income of Rs. 380.7184 crores during the period ended March 31, 2022 as compared to Rs. 456.2704 crores during the period ended December 31, 2021.
The company has posted net profit / (loss) of Rs. 91.6680 crores for the period ended March 31, 2022 as against net profit / (loss) of Rs. 160.0690 crores for the period ended December 31, 2021.
The company has reported EPS of Rs. 3.60 for the period ended March 31, 2022 as compared to Rs. 6.29 for the period ended December 31, 2021.
| Financials | Q4 FY2022 | Q3 FY2022 | % Change |
| Total Income | ₹ 380.7184 crs | ₹456.2704 crs |  -16.56% |
| Net Profit | ₹91.6680 crs | ₹160.0690 crs | -42.73% |
| EPS | ₹3.60 | ₹6.29 | -42.77% |
Financial Results (Q4 FY2022) - YoY Comparison
The company has reported total income of Rs. 380.7184 crores during the period ended March 31, 2022 as compared to Rs.262.4630 crores during the period ended March 31, 2021.
The company has posted net profit / (loss) of Rs.91.6680 crores for the period ended March 31, 2022 as against net profit / (loss) of Rs.83.1159 crores for the period ended March 31, 2021.
The company has reported EPS of Rs.3.60 for the period ended March 31, 2022 as compared to Rs.3.27 for the period ended March 31, 2021.
| Financials | Q4 FY2022 | Q4 FY2021 | % Change |
| Total Income | ₹ 380.7184 crs | ₹262.4630 crs |  45.06% |
| Net Profit | ₹91.6680 crs | ₹83.1159 crs | 10.29% |
| EPS | ₹3.60 | ₹3.27 | 10.09% |
Financial Results (Year Ended FY2022) - YoY Comparison
The company has reported total income of Rs.1412.6024 crores during the Financial Year ended March 31, 2022 as compared to Rs.1023.9555 crores during the Financial Year ended March 31, 2021.
The company has posted net profit / (loss) of Rs.453.8049 crores for the Financial Year ended March 31, 2022 as against net profit / (loss) of Rs.362.3418 crores for the Financial Year ended March 31, 2021.
The company has reported EPS of Rs.17.83 for the Financial Year ended March 31, 2022 as compared to Rs.14.23 for the Financial Year ended March 31, 2021.
| Financials | Year Ended FY2022 | Year Ended FY2021 | % Change |
| Total Income | ₹1412.6024 crs | ₹1023.9555 crs | 37.96% |
| Net Profit | ₹453.8049 crs | ₹362.3418 crs | 25.24% |
| EPS | ₹17.83 | ₹14.23 | 25.30% |
Shares of Suven Pharmaceuticals Limited was last trading in BSE at Rs. 579.45 as compared to the previous close of Rs. 573.90. The total number of shares traded during the day was 14591 in over 1437 trades.
The stock hit an intraday high of Rs. 585.50 and intraday low of 564.70. The net turnover during the day was Rs. 8375521.00.
